According to the literature, the combination of the DNA-PK inhibitor M3814 with type 2 TOPO inhibitors, including doxorubicin, etoposide, and pegylated liposomal doxorubicin, has enhanced the efficacy of type 2 TOPO inhibitors in mouse xenograft ovarian cancer models 61. Here, PRKDC is linked to ovarian carcinoma.